New hope for rare autoimmune disease: obinutuzumab targets relapse

NCT ID NCT06940661

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Apr 12, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study tests whether the drug obinutuzumab can safely bring the disease under control in people with a relapsing form of PR3-ANCA vasculitis (Wegener's). About 33 adults with active disease will receive the drug and be followed for 6 months. The goal is to stop symptoms, clear the blood marker, and reduce steroid use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques"
RECRUITING

Paris, 75014, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GRANULOMATOSIS WITH POLYANGIITIS